News Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Real-time Estimate Cboe BZX Other stock markets 02:14:06 2024-04-24 pm EDT			5-day change	1st Jan Change
29.2 ^USD	+1.23%		-0.21%	-9.81%

Apr. 11	Harmony Biosciences, Bioprojet Enter Licensing Deal for Sleep Disorder Therapy	MT
Apr. 03	Harmony Biosciences Begins Phase 3 Trial of Pitolisant to Treat Prader-Willi Syndrome Symptoms	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024	Apr. 16	PR
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST	Apr. 12	AQ
Harmony Biosciences, Bioprojet Enter Licensing Deal for Sleep Disorder Therapy	Apr. 11	MT
Harmony Biosciences Begins Phase 3 Trial of Pitolisant to Treat Prader-Willi Syndrome Symptoms	Apr. 03	MT
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME	Apr. 03	PR
Harmony Biosciences Initiates Global Phase 3 Registrational Trial (Tempo Study) of Pitolisant in Patients with Prader-Willi Syndrome	Apr. 03	CI
HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE	Mar. 26	PR
Harmony Biosciences Holdings Insider Sold Shares Worth $383,328, According to a Recent SEC Filing	Mar. 19	MT
Transcript : Harmony Biosciences Holdings, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 03:35 PM	Mar. 12
Harmony Biosciences Certified as a Great Place to Work for Sixth Consecutive Year, Underscoring Ongoing Commitment to Employee Satisfaction and Growth	Mar. 07	AQ
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES	Feb. 28	PR
Mizuho Securities Cuts Price Target on Harmony Biosciences to $40 From $42, Maintains Buy Rating	Feb. 27	MT
HARMONY BIOSCIENCES EXPANDS COMMITMENT TO THE RARE NEUROLOGICAL DISEASE COMMUNITY WITH CALL FOR PROGRESS AT THE HEART AND PATIENTS AT THE HEART APPLICATIONS	Feb. 27	AQ
Needham Cuts Price Target on Harmony Biosciences to $50 From $53, Maintains Buy Rating	Feb. 23	MT
Harmony Biosciences Holdings' Q4 Adjusted Net Income Falls, Net Product Revenue Rises; 2024 Revenue Guidance Issued	Feb. 22	MT
Transcript : Harmony Biosciences Holdings, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Tranche Update on Harmony Biosciences Holdings, Inc.'s Equity Buyback Plan announced on October 31, 2023.	Feb. 22	CI
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Earnings Flash (HRMY) HARMONY BIOSCIENCES Posts Q4 EPS $0.73, vs. Street Est of $0.91	Feb. 22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Summary

Filters